Newcelx Ltd (NCEL) Stock Price, Quote & News

Company Profile

NewcelX Ltd., a biotechnology company, engages in developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company was founded in 2008 and is headquartered in Zurich, Switzerland.

Industry: Biotechnology

Sector: Healthcare

Phone: 41 44 512 21 50

Fax: 41 44 512 21 51

Website: newcelx.com

Address:

The Circle 6, Zurich, Switzerland

yoni30 May. 6 at 6:37 PM

$NCEL How much longer will we wait for the start of the experiment?

0 · Reply

yoni30 May. 6 at 6:35 PM

$NCEL Without a supportive message, we will vomit everything And this is what happens

0 · Reply

islandpunk May. 4 at 8:29 PM

$NCEL 13D filed for 25% https://www.sec.gov/Archives/edgar/data/1783036/000121390026051611/xslSCHEDULE_13D_X02/primary_doc.xml

0 · Reply

topstockalerts May. 1 at 12:23 AM

$NCEL this is one of those setups you don’t want to ignore

0 · Reply

intrader Apr. 30 at 7:00 PM

$NCEL I'm all out.

0 · Reply

ScorpionScarlet Apr. 30 at 3:40 PM

$NCEL type I diabetes! Always a winner! 🥳🥳💕💰

0 · Reply

ObsidianClaw Apr. 30 at 12:21 AM

$NCEL on watch

0 · Reply

yoni30 Apr. 28 at 9:33 PM

$NCEL Just as the stock rose quickly and sharply, it fell quickly and sharply Until the experiment starts, we will probably see this

0 · Reply

Trekingirl Apr. 27 at 9:52 PM

$NCEL Sold last week. Back in.

0 · Reply

Zardiw Apr. 27 at 4:23 PM

$YAAS - Called before Run - #DDAmanda Chart Also found early: $REPL $TZOO $NCEL Lots more at: https://DDAmanda.com

0 · Reply

NewcelX files to sell 2.26M common shares for holders

Apr 30, 2026, 8:15 AM EDT - 13 days ago

NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026

2026-04-20T11:43:42.000Z - 23 days ago

NewcelX announces release of updated presentation on Type 1 Diabetes program

ELDN

Apr 20, 2026, 7:37 AM EDT - 23 days ago

NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference

Apr 1, 2026, 7:21 AM EDT - 6 weeks ago

NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing

2026-03-09T11:12:39.000Z - 2 months ago

NewcelX announces research agreement with Eledon Pharmaceuticals

ELDN

Mar 9, 2026, 7:00 AM EDT - 2 months ago

NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes

ELDN

Feb 12, 2026, 7:00 AM EST - 3 months ago

NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy

Jan 29, 2026, 7:00 AM EST - 3 months ago

NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences

Jan 12, 2026, 7:00 AM EST - 4 months ago

NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression

Jan 5, 2026, 7:00 AM EST - 4 months ago

NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board

Dec 11, 2025, 7:00 AM EST - 5 months ago

NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China

Nov 17, 2025, 7:00 AM EST - 6 months ago

NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute

Nov 6, 2025, 7:00 AM EST - 6 months ago

NewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory Board

Nov 4, 2025, 7:00 AM EST - 6 months ago

NewcelX CEO Issues Letter to Shareholders

Nov 3, 2025, 8:25 AM EST - 6 months ago

NewcelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmaceutics Ltd.

NLSP

yoni30 May. 6 at 6:37 PM

$NCEL How much longer will we wait for the start of the experiment?

0 · Reply

yoni30 May. 6 at 6:35 PM

$NCEL Without a supportive message, we will vomit everything And this is what happens

0 · Reply

islandpunk May. 4 at 8:29 PM

$NCEL 13D filed for 25% https://www.sec.gov/Archives/edgar/data/1783036/000121390026051611/xslSCHEDULE_13D_X02/primary_doc.xml

0 · Reply

topstockalerts May. 1 at 12:23 AM

$NCEL this is one of those setups you don’t want to ignore

0 · Reply

intrader Apr. 30 at 7:00 PM

$NCEL I'm all out.

0 · Reply

ScorpionScarlet Apr. 30 at 3:40 PM

$NCEL type I diabetes! Always a winner! 🥳🥳💕💰

0 · Reply

ObsidianClaw Apr. 30 at 12:21 AM

$NCEL on watch

0 · Reply

yoni30 Apr. 28 at 9:33 PM

$NCEL Just as the stock rose quickly and sharply, it fell quickly and sharply Until the experiment starts, we will probably see this

0 · Reply

Trekingirl Apr. 27 at 9:52 PM

$NCEL Sold last week. Back in.

0 · Reply

Zardiw Apr. 27 at 4:23 PM

$YAAS - Called before Run - #DDAmanda Chart Also found early: $REPL $TZOO $NCEL Lots more at: https://DDAmanda.com

0 · Reply

PlutoAnalyses Apr. 24 at 12:58 PM

$ELDN also eyeing the NewcelX partnership for Type 1 Diabetes. This would potentially address the supply bottleneck for islet transplants and fundamentally change ELDN’s valuation. We just need $NCEL’s drug to advance.

1 · Reply

topstockalerts Apr. 23 at 11:34 PM

Top Gainers PT2 $SST $NCEL $AMST $BURU $WYHG

0 · Reply

topstockalerts Apr. 23 at 8:35 PM

Top Gainers $EUDA $TDIC $NCEL $CPIX $AMST

0 · Reply

topstockalerts Apr. 23 at 8:01 PM

$NCEL not the biggest move today, but definitely one of the cleanest

0 · Reply

moneywellspent Apr. 23 at 7:49 PM

$NCEL strong accumulation here

0 · Reply

amir10 Apr. 23 at 7:46 PM

$IONQ take profits to $NCEL

0 · Reply

topstockalerts Apr. 23 at 7:32 PM

$NCEL new HOD 🙌

0 · Reply

Crypto_Cartel Apr. 23 at 7:26 PM

$NCEL

0 · Reply

RETAlerts Apr. 23 at 7:16 PM

$NCEL up 9.4% — tight float mechanics at work. Fewer shares available = amplified moves on volume. This is textbook squeeze set...

0 · Reply

topstockalerts Apr. 23 at 7:02 PM

Top Gainers $EUDA $TDIC $CPIX $AUUD $NCEL

0 · Reply

Trekingirl Apr. 23 at 5:15 PM

$SKLZ oh my! What a day! Good times! $NCEL

0 · Reply

Trekingirl Apr. 23 at 4:56 PM

$NCEL Holy fuck! And Yee Haw!

0 · Reply

Market Cap	17.91M
Revenue (ttm)	0.00
Net Income (ttm)	-8.30M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.05

Volume	14,100
Avg Vol	45,932
Day's Range	N/A - N/A
Shares Out	5.35M
Stochastic %K	19%
Beta	1.01
Analysts	Strong Buy
Price Target	N/A